{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.1","upperLimit":"1.3","value":"1.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"description":"Median amount of time from the start of treatment until first documented response as defined by the International Myeloma Working Group uniform response criteria\n\nStringent CR: Same as CR plus normal free light chain ratio and absence of clonal cells plasma cells in bone marrow (BM) CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\<5% plasma cells in BM VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \\<100 mg per 24 hours PR: ≥50% reduction of serum M-protein and reduction in 24-h urinary M-protein by ≥90% or to \\<200 mg per 24 hours. If the serum and urinary M-protein are not measurable, additional criteria are used to assess PR that will not fit in the space provided here. If present at baseline, a ≥50% reduction in the size of plasmacytomas is also required","dispersionType":"95% Confidence Interval","groups":[{"description":"Induction (Cycles 1-9): Lenalidomide orally, days 1-21. Bortezomib injection, days 1, 8, 15, 22. Dexamethasone orally, days 1, 2, 8, 9, 15, 16, 22, 23 (for subjects 75 years of age or younger), or Dexamethasone orally days 1, 8, 15, 22 (for subjects greater than 75 years of age)\n\nConsolidation (cycles 10-15): Lenalidomide po daily (1-21). Bortezomib sc on days 1, 15\n\nLenalidomide\n\nBortezomib\n\nDexamethasone","id":"OG000","title":"Treatment Arm"}],"paramType":"MEDIAN","populationDescription":"Participants that achieved a response","reportingStatus":"POSTED","timeFrame":"From the start of treatment until the time of first documented response, median duration of 1.1 months","title":"Median Time to Response","type":"SECONDARY","unitOfMeasure":"Months"}